The Roche-CHUS Joint Unit is a joint initiative between Roche Farma S.A. and The Group of Translational Medical Oncology of the Health Research Institute in Santiago de Compostela – IDIS, whose aim is to develop innovative solutions to improve diagnosis, treatment, evaluation and monitoring of breast and prostate cancers in an individualised manner. Focusing on the study of metastatic processes to obtain results with clinical applications, the aim is that the study results offer the health system practical solutions in the shortest possible time, thereby improving the expectations and quality of life of patients through precision oncology.

The Joint Unit is configured as a translational project involving oncologists and researchers from different disciplines; molecular and cell biology, liquid biopsy, preclinical models, and chemistry, in collaboration with the multinational company Roche. This multidisciplinary and collaborative environment makes the UMR most suitable for the development of innovative health projects.
The Joint Unit is configured as a translational project involving oncologists and researchers from different disciplines; molecular and cell biology, liquid biopsy, preclinical models, and chemistry, in collaboration with the multinational company Roche. This multidisciplinary and collaborative environment makes the UMR most suitable for the development of innovative health projects.
Lines of Investigation
Team

Job Offers
Location and Contact
Address:
Hospital Gil Casares, Ground Floor
Complexo Hospitalario Universitario de Santiago de Compostela
Travesía da Choupana S/N, Santiago de Compostela (A Coruña)
P.C:15706
Telephone
- Laboratory:
+34 981 95 56 11 - Management and Administration:
+34 981 95 56 02
La Unidad Mixta Roche-Chus está cofinanciada por la Axencia Galega de Innovación, GAIN de la Xunta de Galicia: “Subvención a organismos de investigación de Galicia para a creación, posta en marcha e impulso de Unidades Mixtas de Investigación” de la Xunta de Galicia en el marco del Plan Galego de Investigación, Innovación e Crecemento- i2C.